{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:01:51Z","timestamp":1768885311982,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012381","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000}}],"reference-count":91,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012381.pub2","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T02:58:36Z","timestamp":1580093916000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis"],"prefix":"10.1002","volume":"2020","author":[{"given":"Sarah C","family":"Davies","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine & Dentistry; University of Western Ontario; London Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isra M","family":"Hussein","sequence":"additional","affiliation":[{"name":"Faculty of Medicine; University of Toronto; Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tran M","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; London Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire E","family":"Parker","sequence":"additional","affiliation":[{"name":"Robarts Clinical Trials; London Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reena","family":"Khanna","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Western Ontario; London Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Western Ontario; London Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,1,27]]},"reference":[{"key":"10.1002\/14651858.CD012381.pub2-BIB0001|cit1","first-page":"A62","article-title":"Tofacitinib, an oral jak inhibitor, in the treatment of ulcerative colitis: open-label, long-term extension study","volume":"67","author":"Bloom","year":"2018","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1093\/ecco-jcc\/jjx180.178","article-title":"Lower incidence of herpes zoster in vedolizumab-treated vs. tofacitinib-treated patients with ulcerative colitis","volume":"12","author":"Caldera","year":"2018","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"S050","DOI":"10.1093\/ecco-jcc\/jjy222.075","article-title":"Efficacy and safety of open-label treatment with tofacitinib 10 Mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the Octave studies","volume":"13","author":"Chiorean","year":"2019","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1016\/S0016-5085(19)37215-4","article-title":"Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies","volume":"156","author":"Chiorean","year":"2019","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD012381.pub2-BIB0005|cit5","first-page":"A255","article-title":"Maintenance of remission with tofacitinib in patients with ulcerative colitis: subpopulation analysis from an open-label, long-term extension study","volume":"6","author":"Colombel","year":"2018","journal-title":"United European Gastroenterology Journal"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD012381.pub2-BIB0006|cit6","first-page":"S4","article-title":"Maintenance of remission with tofacitinib in patients with ulcerative colitis: subpopulation analysis from an open-label, long-term extension study","volume":"113","author":"Colombel","year":"2018","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"S1102","DOI":"10.1016\/S0016-5085(19)39716-1","article-title":"Improvement in patient-reported inflammatory bowel disease questionnaire outcomes, and relationship with disease activity, in tofacitinib treated patients with ulcerative colitis: data from the OCTAVE clinical trials","volume":"156","author":"Dubinsky","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"S462","DOI":"10.1093\/ecco-jcc\/jjy222.809","article-title":"Improvement in patient-reported inflammatory bowel disease questionnaire outcomes, and relationship with disease activity, in tofacitinib-treated patients with ulcerative colitis: data from the Octave clinical trials","volume":"13","author":"Dubinsky","year":"2019","journal-title":"Journal of Crohn's & Colitis"},{"issue":"8","key":"10.1002\/14651858.CD012381.pub2-BIB0009|cit9","first-page":"A121","article-title":"Time to loss of efficacy following tofacitinib interruption in patients with ulcerative colitis: results from octave sustain","volume":"6","author":"Dubinsky","year":"2018","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.14309\/00000434-201710001-00640","article-title":"Efficacy of tofacitinib in patients with ulcerative colitis by prior tumor necrosis factor inhibitor treatment status: results from octave induction and maintenance studies","volume":"112","author":"Dubinsky","year":"2017","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"S301","DOI":"10.1093\/ecco-jcc\/jjy222.512","article-title":"Analysis of the impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis programme","volume":"13","author":"Farraye","year":"2019","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S1111","DOI":"10.1016\/S0016-5085(19)39739-2","article-title":"Analysis of the impact of body mass index on efficacy and safety in the tofacitinib Octave ulcerative colitis program","volume":"156","author":"Farraye","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"S329","DOI":"10.14309\/00000434-201710001-00607","article-title":"Tofacitinib for maintenance therapy in patients with active ulcerative colitis in the phase 3 octave sustain trial: results by local and central endoscopic assessments","volume":"112","author":"Feagan","year":"2017","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0014|cit14","first-page":"A25","article-title":"Tofacitinib for maintenance therapy in patients with active ulcerative colitis in the phase 3 octave sustain trial: results by local and central endoscopic assessments","volume":"5","author":"Feagan","year":"2017","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S477","DOI":"10.1093\/ecco-jcc\/jjy222.836","article-title":"Tofacitinib efficacy in patients with moderate to severe ulcerative colitis: subgroup analyses of OCTAVE Induction 1 and 2 and OCTAVE sustain by 5-aminosalicylates use","volume":"13","author":"Hanauer","year":"2019","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1093\/ecco-jcc\/jjx180.062","article-title":"Tofacitinib for the treatment of ulcerative colitis: analysis of malignancy rates from the OCTAVE clinical programme","volume":"12","author":"Lichtenstein","year":"2018","journal-title":"Journal of Crohn's & Colitis"},{"issue":"8","key":"10.1002\/14651858.CD012381.pub2-BIB0017|cit17","first-page":"A255","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in the treatment of ulcerative colitis: an interim analysis of an open-label, long-term extension study with up to 4.9 years of treatment","volume":"6","author":"Lichtenstein","year":"2018","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0018|cit18","first-page":"A39","article-title":"Tofacitinib, an oral Janus Kinase inhibitor, in the treatment of ulcerative colitis: open-label, long-term extension study","volume":"5","author":"Lichtenstein","year":"2017","journal-title":"United European Gastroenterology Journal"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD012381.pub2-BIB0019|cit19","first-page":"S395","article-title":"Tofacitinib, an oral Janus Kinase inhibitor, in the treatment of ulcerative colitis: open-label, long-term extension study","volume":"112","author":"Lichtenstein","year":"2017","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"S351","DOI":"10.1093\/ecco-jcc\/jjy222.603","article-title":"Analysis of haematological changes in tofacitinib-treated patients with ulcerative colitis across Phase 3 induction and maintenance studies","volume":"13","author":"Lichtenstein","year":"2019","journal-title":"Journal of Crohn's and Colitis"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD012381.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"S1111","DOI":"10.1016\/S0016-5085(19)39738-0","article-title":"Analysis of hematological changes in tofacitinib-treated patients with ulcerative colitis across phase 3 induction and maintenance studies","volume":"156","author":"Lichtenstein","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0022|cit22","first-page":"A299","article-title":"Pregnancy outcomes in the tofacitinib ulcerative colitis octave studies","volume":"(5 Supplement 1","author":"Mahadevan","journal-title":"United European Gastroenterology Journal"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD012381.pub2-BIB0023|cit23","first-page":"S410-11","article-title":"Pregnancy outcomes in the tofacitinib ulcerative colitis octave studies","volume":"112","author":"Mahadevan","year":"2017","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S366","DOI":"10.1093\/ecco-jcc\/jjx180.643","article-title":"Efficacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption: results from the OCTAVE clinical trials","volume":"12","author":"Panes","year":"2018","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S601","DOI":"10.1016\/S0016-5085(17)32148-0","article-title":"Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis","volume":"152","author":"Panes","year":"2017","journal-title":"Gastroenterology"},{"issue":"Supplement 2","key":"10.1002\/14651858.CD012381.pub2-BIB0026|cit26","first-page":"A121","article-title":"Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis","volume":"66","author":"Panes","year":"2017","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1093\/ecco-jcc\/jjx002.592","article-title":"Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis","volume":"11","author":"Panes","year":"2017","journal-title":"Journal of Crohn's and Colitis"},{"issue":"2","key":"10.1002\/14651858.CD012381.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ecco-jcc\/jjx133","article-title":"Tofacitinib in patients with ulcerative colitis: health-related quality of fife in phase 3 randomized controlled induction and maintenance studies","volume":"12","author":"Panes","year":"2017","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0029|cit29","doi-asserted-by":"crossref","unstructured":"Panes J Vermeire S Lindsay JO Sands BE Su C Friedman G Tofacitinib in patients with ulcerative colitis: health-related quality of life in phase 3 randomised controlled induction and maintenance studies Journal of Crohn's & Colitis 2018 12 2 145 56","DOI":"10.1093\/ecco-jcc\/jjx133"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"S1102","DOI":"10.1016\/S0016-5085(19)39715-X","article-title":"Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the Octave open study for tofacitinib delayed responders","volume":"156","author":"Rubin","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1093\/ecco-jcc\/jjy222.077","article-title":"Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders","volume":"13","author":"Rubin","year":"2019","journal-title":"Journal of Crohn's & Colitis"},{"issue":"5 Supplement 1","key":"10.1002\/14651858.CD012381.pub2-BIB0032|cit32","first-page":"A149","article-title":"Integrated safety analyses of tofacitinib in ulcerative colitis clinical trials","volume":"5","author":"Sandborn","year":"2017","journal-title":"United European Gastroenterology Journal"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD012381.pub2-BIB0033|cit33","first-page":"S403","article-title":"Integrated safety analyses of tofacitinib in ulcerative colitis clinical trials","volume":"112","author":"Sandborn","year":"2017","journal-title":"American Journal of Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD012381.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD012381.pub2-BIB0035|cit35","first-page":"S45","article-title":"Tofacitinib for the treatment of ulcerative colitis: up to 4.4 years of safety data from global clinical trials","volume":"12","author":"Sandborn","year":"2018","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1093\/ecco-jcc\/jjy222.590","article-title":"Tofacitinib for the treatment of ulcerative colitis: up to 5.4 years of safety data from global clinical trials","volume":"13","author":"Sandborn","year":"2019","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1093\/ecco-jcc\/jjx002.031","article-title":"Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial","volume":"11","author":"Sandborn","year":"2017","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/S0016-5085(17)30971-X","article-title":"Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomized controlled trial","volume":"152","author":"Sandborn","year":"2017","journal-title":"Gastroenterology"},{"issue":"18","key":"10.1002\/14651858.CD012381.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0040|cit40","first-page":"30491","article-title":"Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis","volume":"19","author":"Sands","year":"2019","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000502144","article-title":"Tofacitinib as induction and maintenance therapy in Japanese patients with active ulcerative colitis","volume":"4","author":"Suzuki","year":"2019","journal-title":"Inflammatory Intestinal Diseases"},{"issue":"1","key":"10.1002\/14651858.CD012381.pub2-BIB0042|cit42","first-page":"S351-2","article-title":"Tofacitinib for the treatment of ulcerative colitis: analysis of infection rates from the OCTAVE clinical programme","volume":"12","author":"Winthrop","year":"2018","journal-title":"Journal of Crohn's & Colitis"},{"issue":"10","key":"10.1002\/14651858.CD012381.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1016\/S0016-5085(14)61331-7","article-title":"The relationship of tofacitinib plasma concentration to clinical efficacy in ulcerative colitis patients in a dose-ranging phase 2 study","volume":"1","author":"Mukherjee","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"S764","DOI":"10.1016\/S0016-5085(13)62825-5","article-title":"Evaluation of the relationship between fecal calprotectin concentrations and clinical and endoscopic outcome measures in a phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"1","author":"Sandborn","year":"2013","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD012381.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1016\/S0016-5085(11)60445-9","article-title":"Phase 2 study of CP-690,550, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"1","author":"Sandborn","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"S060","DOI":"10.1093\/ecco-jcc\/jjy222.087","article-title":"Clinical, endoscopic, histological and biomarker activity following treatment with the gut-selective, pan-JAK inhibitor TD-1473 in moderately to severely active ulcerative colitis","volume":"13","author":"Sandborn","year":"2019","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1093\/ibd\/izy393.046","article-title":"The gut-selective, orally administered, pan-jak inhibitor TD-1473 demonstrates favorable safety, tolerability, pharmacokinetic, and signal for clinical activity in subjects with moderately-to-severely active ulcerative colitis","volume":"25","author":"Sandborn","year":"2019","journal-title":"Inflammatory Bowel Diseases"},{"issue":"10","key":"10.1002\/14651858.CD012381.pub2-BIB0050|cit50","first-page":"1588","article-title":"The intestinally restricted, orally administered, PAN-JAK inhibitor TD-1473 demonstrates favorable safety, tolerability, pharmacokinetics, and signal for clinical activity in subjects with moderately-to-severely active ulcerative colitis","volume":"6","author":"Sandborn","year":"2018","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"S319","DOI":"10.14309\/00000434-201610001-00709","article-title":"Tofacitinib for induction therapy in patients with active ulcerative colitis in two phase 3 clinical trials: Results by local and central endoscopic assessments","volume":"111","author":"Feagan","year":"2016","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0052|cit52","first-page":"S283","article-title":"Improvement in patient-reported outcomes in 2 Phase 3 studies of tofacitinib in patients with moderately to severely active ulcerative colitis","volume":"10","author":"Panes","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"S1003","DOI":"10.1016\/S0016-5085(16)33395-9","article-title":"Improvement in patient-reported outcomes in two phase 3 induction studies of tofacitinib in patients with moderately to severely active ulcerative colitis","volume":"1","author":"Panes","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0054|cit54","first-page":"S157","article-title":"Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate to severe ulcerative colitis: results from two phase 3 randomized controlled trials","volume":"1","author":"Sandborn","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.14309\/00000434-201610001-00569","article-title":"Onset of efficacy of tofacitinib for induction therapy in patients with active ulcerative colitis in two multinational, phase 3 clinical trials","volume":"111","author":"Sandborn","year":"2016","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0056|cit56","first-page":"S15","article-title":"Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate-to-severe ulcerative colitis: results from 2 phase 3 randomised controlled trials","volume":"10","author":"Sandborn","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"S261","DOI":"10.14309\/00000434-201610001-00570","article-title":"Tofacitinib has induction efficacy in moderately to severely active ulcerative colitis, regardless of prior TNF inhibitor therapy","volume":"111","author":"Sands","year":"2016","journal-title":"American Journal of Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD012381.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1158-69","DOI":"10.1093\/ecco-jcc\/jjy085","article-title":"Peficitinib, an oral Janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomised, phase 2 study","volume":"12","author":"Sands","year":"2018","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0059|cit59","unstructured":"A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of upadacitinib (ABT-494) for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis ClinicalTrials.gov\/show\/NCT02819635"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0060|cit60","unstructured":"Combined phase 2b\/3, double-blind, randomized, placebo-controlled studies evaluating the efficacy and safety of filgotinib in the induction and maintenance of remission in subjects with moderately to severely active ulcerative colitis (SELECTION1) ClinicalTrials.gov\/show\/NCT02914522"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0061|cit61","unstructured":"A phase 3B\/4, multi-center, double-blind, randomized, parallel group study of tofacitinib (CP-690,550) In subjects with ulcerative colitis in stable remission ClinicalTrials.gov\/show\/NCT03281304"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0062|cit62","unstructured":"A phase 2, double-blind, dose-ranging, placebo-controlled study with open-label extension to evaluate the safety and efficacy of itacitinib in moderate to severe ulcerative colitis ClinicalTrials.gov\/show\/NCT03627052"},{"issue":"3","key":"10.1002\/14651858.CD012381.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.gtc.2014.05.011","article-title":"Update on Janus kinase antagonists in inflammatory bowel disease","volume":"43","author":"Boland","year":"2014","journal-title":"Gastroenterology Clinics of North America"},{"issue":"4-5","key":"10.1002\/14651858.CD012381.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.autrev.2014.01.028","article-title":"Diagnosis and classification of ulcerative colitis","volume":"13","author":"Conrad","year":"2014","journal-title":"Autoimmunity Reviews"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2013.06.007","article-title":"Involvement of JAK\/STAT signalling in the pathogenesis of inflammatory bowel disease","volume":"76","author":"Coskun","year":"2013","journal-title":"Pharmacological Research"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1152\/ajpgi.00311.2015","article-title":"JAK inhibition using tofacitinib for inflammatory bowel disease treatment: ahub for multiple inflammatory cytokines","volume":"310","author":"Danese","year":"2016","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"759-73","DOI":"10.1124\/dmd.113.054940","article-title":"The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metabolism and Disposition"},{"issue":"7109","key":"10.1002\/14651858.CD012381.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD012381.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.mayocp.2014.07.002","article-title":"Ulcerative colitis: epidemiology, diagnosis, and management","volume":"89","author":"Feuerstein","year":"2014","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012381.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/art.33383","article-title":"Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs","volume":"64","author":"Fleischmann","year":"2012","journal-title":"Arthritis and Rheumatism"},{"issue":"7650","key":"10.1002\/14651858.CD012381.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7414","key":"10.1002\/14651858.CD012381.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-anlayses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0074|cit74","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editors(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0075|cit75","unstructured":"Higgins JP Altman DG Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editors(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"3","key":"10.1002\/14651858.CD012381.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1053\/j.gastro.2006.01.048","article-title":"American gastroenterological association institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease","volume":"130","author":"Lichtenstein","year":"2006","journal-title":"Gastroenterology"},{"issue":"3 Supp 1","key":"10.1002\/14651858.CD012381.pub2-BIB0077|cit77","first-page":"1","article-title":"Emerging treatment options in mild to moderate ulcerative colitis","volume":"11","author":"Lichtenstein","year":"2015","journal-title":"Gastroenterology and Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012381.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences","volume":"126","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"Journal of Inflammation (London, England)"},{"issue":"9853","key":"10.1002\/14651858.CD012381.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative Colitis","volume":"380","author":"Ord\u00e1s","year":"2012","journal-title":"Lancet"},{"issue":"22","key":"10.1002\/14651858.CD012381.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012381.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ecco-jcc\/jjx133","article-title":"Tofacitinib in patients with ulcerative colitis: Health-related quality of life in phase 3 randomised controlled induction and maintenance studies","volume":"12","author":"Panes","year":"2018","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0083|cit83","unstructured":"Medication guide for XELJANZ\/ XELJANZ XR http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959&section=MedGuide#side effects"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0084|cit84","unstructured":"Prescribing information for XELJANZ\/ XELJANZ XR http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959#S14.3"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0085|cit85","first-page":"237","article-title":"A clinical review of recent findings in the epidemiology of inflammatory bowel disease","volume":"5","author":"Ponder","year":"2013","journal-title":"Clinical Epidemiology"},{"issue":"30","key":"10.1002\/14651858.CD012381.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.3748\/wjg.v12.i30.4819","article-title":"Extraintestinal manifestations and complications in inflammatory bowel diseases","volume":"12","author":"Rothfuss","year":"2006","journal-title":"World Journal of Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD012381.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012381.pub2-BIB0088|cit88","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editors(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration Available from\u00acwww.cochrane-handbook.org"},{"issue":"8","key":"10.1002\/14651858.CD012381.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care and Research"},{"issue":"24","key":"10.1002\/14651858.CD012381.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.2146\/news120088","article-title":"FDA approves tofacitinib for rheumatoid arthritis","volume":"69","year":"2012","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"10","key":"10.1002\/14651858.CD012381.pub2-BIB0091|cit91","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012381","article-title":"Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis","author":"Hussein","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012381.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T23:06:16Z","timestamp":1628550376000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD012381.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Gut Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,27]]},"references-count":91,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012381.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,27]]}}}